The GLP-1 Affordability Transformation: Prices Fell 75%+ in 18 Months

In early 2025, brand-name GLP-1 medication cost $1,000-1,400/month without insurance. By mid-2026, the same class of medication is available for $50-245/month through multiple pathways. This 75-96% price decline is one of the fastest drug pricing corrections in modern pharmaceutical history.

What Drove the Collapse

1. Government-negotiated pricing

The TrumpRx program negotiated agreements with Novo Nordisk and Eli Lilly, setting brand-name GLP-1 prices at $245/month — less than a quarter of previous retail. The Medicare GLP-1 Bridge program further reduced patient costs to $50/month for eligible beneficiaries.

2. Oral competition

Foundayo (orforglipron) and Ozempic tablets introduced oral alternatives that are cheaper to manufacture. Small molecules don't require the expensive peptide synthesis and cold-chain logistics of injectable formulations. Novo Nordisk set self-pay oral semaglutide at $149/month — competitive with compounding prices.

3. Compounding market pressure

The compounding industry demonstrated price elasticity: compounded semaglutide at $99-300/month proved that the market could function at far lower price points. While compounding faces regulatory headwinds, it permanently shifted patient expectations about what GLP-1 medication should cost.

4. Insurance expansion

More commercial insurers added GLP-1 coverage as evidence for cardiovascular, kidney, and liver benefits accumulated. Manufacturer copay cards (reducing copays to $25-50/month) made insured access nearly universal for covered patients.

Current Price Landscape

Historical Context

This correction mirrors — but exceeds in speed — what happened with statins, blood pressure medications, and HIV antiretrovirals in earlier decades. Competition, generic/alternative entry, and government intervention converged to transform expensive specialty medications into broadly accessible treatments.